The multistage model is tested on several human and animal data sets. It fits in some cases but not in others. With human lung cancer data, there is a drop in risk for ex-smokers quite different from the predictions of the model. The results are not conclusive but are compatible with the view that the multistage model provides a family of curves that often fit cancer incidence data, but may not capture the underlying biological reality.
Introduction
The Armitage-Doll multistage model says in essence that a cell progresses to malignancy through the states of a Markov chain (1) . This model is often used in cancer risk assessment for example, by the U.S. Environmental Protection Agency (2) , and it is often cited in discussions of the biological mechanisms of cancer, for example, by the International Agency for Research on Cancer (3). It therefore seems worthwhile to review the model and assess its fit to some of the main available data sets, which is the object of the present paper. Tb state the model a bit more carefully (4-6): A normal cell goes through a definite sequence of stages until it becomes cancerous. Absent carcinogenic exposure, waiting times in the various stages are assumed to be independent, exponential random variables. So, there is a background rate of progression through each stage, which may be different for the different stages.
An animal or a human tissue is a collection of cells and fails (gets cancer) when the first cell in the collection fails. Thus, the failure time for the tissue is the minimum of the failure times of its component cells. Different cells are assumed to be independent with identically distributed failure times.
The next assumption: If a subject is exposed to a carcinogen such as tobacco smoke, the rate of progression through the various stages increases in proportion to dose; the constant of proportionality depends on the stage. For the insensitive stages, this constant is zero; for the sensitive stages, the constant of proportionality is positive. Stages that may be estimated as sensitive or insensitive, depending on how the data turn out, will be termed "potentially sensitive?'
In order for the usual approximations to work, it is also necessary to assume that the time to pass through a stage tends to be much larger than the lifetime of the animal (7) . The rates of progression through the various stages are assumed to be the same for all cells and all subjects. In risk assessment, constancy of certain rates is assumed even across species.
With a final assumption, independence of competing risks, the model can be used to generate a likelihood function for data; parameters can be estimated by maximum likelihood. Then the adequacy of the fit can be assessed by a chi-squared test. The intent was to follow this strategy rigorously, but we ended up making some approximations for mathematical convenience, others to get numerical algorithms to converge, and still others to accommodate experimental designs.
In a strict modeling approach, the details become quite irritating. Perhaps as a result, most published efforts to assess the fit of the model tend to involve simple approximations to the likelihood function, and goodness-of-fit tests are seldom made (8) (9) (10) (11) . On the other hand, the statistical strategy followed here is similar to that in Brown and Hoel (12) (13) .
There are many variations on the model, for example, allowing a latency period between malignancy and the clinically observable end point. Polynomial dose response at each stage has also been considered and transitions from higher order to lower order states. Dose thresholds are sometimes used or nonlinear transformations of time. Random parameters are another option. There is little doubt that, given a data set, one variation on the model or another can be made to fit. Our question runs the other way round: Given a version of the model, will it fit a variety of data sets? For that purpose, we elected to start with the version described here, which is relatively simple and in general circulation.
Versions of the model are widely used in risk assessment, although their biological basis is more than a little obscure. In particular, despite remarkable progress on the (5, (14) (15) (16) (17) (18) . Striking recent papers on the genetics of cancer include Bodmer et al. (19) , Naylor et al. (20) , and Solomon et al. (21) .
Results

Overview
This section will review the data sets considered and summarize conclusions ( Table 1 ). The most carefully studied application of the model is to lung cancer, which is considered first; then comes experimental data on animals.
Other Findings on Lung Cancer. For the British doctors, the Dorn veterans, and the ACS males, the model overpredicts around the edges of the data set. Models fitted to continuing smokers do not predict the risk for exsmokers at all well: The models predict that excess risk will continue to increase (or stay constant) after quitting, while the data show a decrease.
Human Lung Cancer
British Doctors. Doll and Peto report on smoking and lung cancer in their seminal cohort study of British doctors (9) . The data quality is considered to be excellent; dose was ascertained on three separate occasions. One drawback is the absence of information on age at start of smoking; following Doll and Peto, this is imputed as 22.5 years (including some allowance for the time from malignancy to death). Furthermore, although the study lasted 20 years with about 34 ,000 subjects, the number of events (lung cancer cases) is relatively small.
The data set used here, reported in Doll and Peto (9) , selects only subjects who smoked at a nearly constant rate; only 215 events out of 571 are kept. The published data on ex-smokers are not in usable form and the unpublished data do not appear to be available.
Data on nonsmokers or current smokers are summarized. For this cohort, there is a paradoxical drop in risk (events per 1000 person years) for the highest dose group and at the highest ages. This is more readily seen from Doll and Peto's table than from our aggregation (Thbles 2 and 3). A variety of models fit quite well, with five to eight stages; models with four or nine stages did not fit. Previous work suggests five or six as the number of stages. (The plural "models" refers to special cases of the singular "multistage model.")
Is the dose response linear or quadratic? In the multistage model, this comes down to asking whether there is one sensitive stage or two. This question has been much debated. In our models, with five, six, or seven stages, the first and next-to-last appear to be sensitive. With eight stages, the first need not be sensitive. We Rogot (24) and Whittemore (25) (23) .
The data quality may be questioned; in particular, dose was ascertained only once. On the positive side, this data set is quite large (1266 events); it has information on age at start of smoking and it includes ex-smokers. For current male smokers, models with 3 to 10 stages were tried. The best-fitting had 6 stages (X2 = 28 on 13 degrees of freedom, p = 1%); the estimated sensitivity for the fifth stage was negligible. Compared to 1542 events, the fit seems good. However, the pattern of residuals was as in the veterans study. Rates for the nonsmokers, estimated from the current smokers through the model, were much higher than the observed rates. Largely by accident, we got the data on never-smokers or ex-smokers only after fitting the models, so there was a genuine opportunity for cross-validation.
For current female smokers, a variety of models fit, with three to eight stages; the best was five stages; almost any pattern of sensitivity is obtainable. Estimated Some readers may find our approach of fitting the model and testing by chi-squared or making extrapolations and checking them too mechanical. The model does provide a rich and loosely defined class of polynomials for describing data, a heuristic for suggesting hypotheses about biological mechanisms, a demonstration that the power law for incidence rates is compatible with a series of discrete cellular changes, and a source of beautiful mathematical puzzles. If those were the only virtues attributed to the model, our critical approach might be out of line. However, quite literal and dogmatic inferences are sometimes drawn from the model, particularly in the field of risk assessment. A strict approach to testing such a model may be in order.
Other readers may be concerned, and rightly so, about the sample size issue: With a large enough sample, any model may be rejected. Our results do suggest that the multistage model will be accepted when the number of events is relatively small and rejected when the number is relatively large. On the other hand, one conventional argument for the statistical version of the multistage model is that it fits the data. While failure to fit may not prove the model to be wrong, it cannot show the model to be right. Patterns of error in the fit, discrepancies among cohorts, and systematic errors in prediction seem relevant in assessing the merits of the conventional evidence for the model.
Our view is that on the whole, fitting the multistage model to cancer incidence data in humans or in bioassays does not seem likely to yield much new understanding about the mechanisms of cancer, unless the modeling results can be rigorously checked against observable phenomena, in the lab and in human populations. Reliable procedures for estimating cancer risks seem to be a long way off, barring some breakthrough in the biological understanding. Some of the alternative models are worth exploring (18) .
Cook, Doll, and Fellingham show that while many cancer incidence data sets fit the model, many others do not, and problems with adjustments are discussed (8) . Doll and Peto felt that the multistage model was a promising avenue to explore "even if current knowledge is too sparse for such models to be tested critically" (9) . Peto reviews the biological evidence (42); Doll and Peto cannot be described as enthusiastic about dose-response models in risk assessment (43) . Also see Wald and Doll (44) . Ar 
Detailed Results for Lung Cancer Introduction
This section will report details of the modeling results on the three main lung cancer data sets: the British doctors, the Dorn veterans, and the ACS volunteers. Lung cancer data are usually modeled with one early stage and one late stage allowed to be sensitive; the first and nextto-last are the conventional choices. Dose will be measured in cigarettes per day; To denotes the age at start of smoking; for ex-smokers, T, denotes the age at quitting.
Consider the hazard rate h(t) given by a multistage model, with the following interpretation: A person who survives to age t has chance h(t)dt of contracting lung cancer in the time interval (t,t + dt). The fornulas for h(t) are derived in Whittemore and Keller (4) A tn-l [1] Atn-i + Bdose(tn-I + Cdose(t -To)'-'
[3] In Equations 4-6, stages 1 and n are potentially sensitive; again, Equation 4 is for nonsmokers, Equation 5 is for current smokers and Equation 6 for ex-smokers. Equation 4 makes sense for n > 3; Equation 5, for n > 2.
Atn-[ [4] Atn-i + Bdose tn-
The number of events in each cell of the basic cross tab ( Table 2 for the British doctors) is taken to be Poisson, and independent from cell to cell. The expected number in a cell is the hazard rate times the number of person years. The latter is treated as constant in the modeling, even though it is slightly random. This last approximation seems to be quite good in the present context (6) ; for asymptotic theory, see Aalen (51) and Jacobsen (52) . The independence of competing risks is needed to compute the expected value.
After suitable aggregation of the data, the coefficients in models Equations 1-3 and Equations 4-6 can be estimated by maximum likelihood, and then the goodness-offit can be assessed by the X2 statistic:
We also considered using the Neyman-Pearson likelihood ratio statistic (or Wilks statistic):
Irs(X) = 2{supOEG log L(XIE) [8] -SUPEO N log L(XIE)})
Here, L is the likelihood function, X the data, and 0 the parameter vector, for example, the 24 Poisson means for the British doctors ( Table 3 ). The first sup is over the set G of all parameter vectors, namely, the saturated Poisson model. The second sup is over N, the set of e's corresponding to multistage models. Simulation results (6) suggest that X2 has close to its asymptotic chi-squared distribution, while lrs is a little too big.
The coefficients A,B,C,D in Equations 1-3 and 4-6 must be nonnegative, and satisfy the constraint AD = BC. The coefficient A reflects background rates only; B includes the sensitivity of the late stage; C, the sensitivity of the early stage; D, the sensitivity of both stages. If B = D = 0, then the late stage is insensitive; if C = D = 0, the early stage is insensitive (6) .
If stages 1 and n are sensitive, ex-smokers show an abrupt drop in predicted risk: As t increases from just below T, to just above T1, the hazard rate jumps down, because terms involving the sensitivity of that stage drop out (compare Eq. 3 with Eq. 6 at t = TI). In other words, the hazard reverts to that of an n-stage model with only the first stage sensitive. This discontinuity is a wellknown feature of last-stage sensitivity and is an argument against such models. The British doctors' data are too thin to reject implausible models. Equally, these data cannot provide strong evidence in favor of preferred models.
British Doctors lables 4 and 5 show the empirical results for the nonsmokers and current smokers among the British doctors, bEstimate has been forced to 0.
CX2 is the difference between the X2s for the restricted and unrestricted models. Next, Table 7 shows the observeds and person-years in the veterans data. Table 8 shows the residuals from the six-stage model in Table 6 . On the whole, the residuals seem to be negative around the edges of the table and positive in the middle. For persons aged 75 or more, some of the discrepancies may be practically significant as well as statistically significant. The data for the ACS men are shown in Table 10 . The residuals in Table 11 resemble the veterans data in pattern of signs. For all three data sets (the doctors, the veterans, and the ACS men), the best-fitting models overpredict risk around the edges. Of course, the model could be right and this pattern could be artifactual.
ACS Volunteers
Many models fit the data for ACS female current smokers including those with no background rate ( 
Ex-Smokers
Models fitted to current smokers do not predict well for ex-smokers, as noted above. The discussion is continued in this section. There seems to be general agreement that when smokers quit, their excess risk freezes (22, 42, 55, 56) . Absolute risk (background + excess) must therefore increase as a function of time since quitting. However, the data show a drop in risk on cessation of smoking.
To illustrate the predictions, Table 13 computes risks from three multistage models: the ones that best fit the nonsmokers or current smokers among the British doctors, the American veterans, and the ACS men (six stages with first and fifth allowed to be sensitive; for the ACS men, the model is fitted to current smokers only). The risks are computed for three groups of men: NON, the nonsmokers; CS, the current smokers with age at start 22.5 and constant dose of a pack a day; EX, the exsmokers, who started smoking like CS but quit at age 50.
Tb compute the table, the models given by Equations 1 and 2 are fitted to the nonsmokers and current smokers to estimate the coefficients A,B,C,D. Then Equation 1 is used to compute the risk for nonsmokers, 2 is used for the current smokers, and 3 is used to project the risk for exsmokers.
One problem is that the projections of the three models are quite discrepant. For an extreme example, take the aThe model overpredicts around the edges and underpredicts in the middle, for current smokers of cigarettes only and nonsmokers. bEstimate has been forced to 0. Table 13 . pected are from the six-stage model of NON CS EX  50  5  58  58  6  67  67  28  38  38  55  8  112  66  9  109  71  45  68  66  60  12  202  78  14  170  76  70  114 110  65  17  348  99  20  254  82  105  185 176  70  25  571 130  30  368  92  152  290 274  75  36  900 175  42  520 104  214  441 412 aAge at start of smoking is 22.5 years, and dose is a pack per day; the ex-smokers quit at age 50. The risks are predicted from multistage models fitted separately to three cohorts. The models are inconsistent with each other, and the results are incompatible with the freezing of excess risk on quitting. Non, nonsmokers; CS, current smokers; Ex, ex-smokers. Table 6 ; it would make the underprediction problem in Table 14 even worse but would partially correct the overprediction. As far as we can tell, the excess risk in fact declines with years since quitting rather than freezing; even the absolute risk (background + excess) declines, quite contrary to the predictions of the model. For the ACS men too, Table 15 shows that the absolute risk (events per 100,000 person years) declines steadily as a function of time since quitting. The first line in Table 15 may be an artifact (sick people quit smoking). The last line may be low due to the missing events for older persons. Even between lines 2 and 3, there may be a survivor bias: The men most at risk die early. However, controlling for age at quitting and dose (by cross-tabulation) makes little difference, so survivor bias does not seem to be a big problem.
The absolute risk does seem to drop with time since quitting for the veterans and ACS males; the rapid increase predicted by the model simply is not there. Ib state the point more sharply, constant excess risk is incompatible with the sensitivity of the first stage, needed so that age at start influences the response; decreasing excess risk is incompatible with any of the models fitted here. (The phenomenon can be incorporated by having random parameters or a long and variable latency period between malignancy and death.)
For the British doctors, data on ex-smokers are not available. However, the risk for ex-smokers seems to be less than their risk at time of quitting, until 20 years after quitting; the numbers are small, but in aggregate, the observed number of events for the ex-smokers is less than predicted from the risk at time of quitting (57) . On the whole, our results are consistent with this finding [for other data and reviews, see (58) (59) (60) (61) ].
For a literature review on lung cancer, see the IARC monograph (55). With bladder cancer, the risk is considered to drop when exposure ceases (55). For experimental results on regression of lesions when carcinogenic in- Unless noted otherwise, we cut the knot by setting latency to zero. This has the advantage of simplicity, but cannot be taken too literally. The problem is serious, because in the end the data are on times to a clinically detectable end point. If a large part of the distribution for that time is left unspecifled, the model is poorly defined.
As a practical matter, allowing positive latency reduces the number of estimated stages, by increasing the rate of change of the fitted hazard function at the relevant time period.
Independence of Competing Risks
Let T be the time to failure for the whole tissue in the multistage model, namely, the time for the first target cell to complete its progression through the n stages of the process. Then the conditional distribution of T given T > t, is assumed equal to the distribution of T given survival on test to time t. (In the latter event, we condition not only that T > t, but that all risks mature after time t.) The assumption of equality is a version of independence of competing risks, which allows the model to be used even when the data on waiting times are censored by death from other causes; and in the case of human subjects, by withdrawal from the study, data selection by the investigators, etc.
This assumption may not be verifiable from the data (69), and we can see only two possible defenses: a) It has been used since the time of Bernoulli; b) it is at present impossible to do risk modeling any other way.
Pooling
For estimation and testing, it is necessary to arrive at some definite aggregation of the data, which in our examples is usually presented in the form of a two-or threedimensional cross-tab. It will be advantageous to pool cells, eliminating the sparse ones. This improves power (up to a point) and makes the null distribution of the X2 statistic closer to the asymptotic limit; for some empirical evidence, see Freedman and Navidi (6) . make the asymptotics of the X2 test go through, the same aggregation must be used for both estimation and testing. For the lung cancer data sets, the aggregation was suggested by the age x dose table in The next object is to explain how aggregate cross-tabs are derived from the raw data, with the current smokers in the British doctors as a first example. The original data are given in Table 2 and the aggregation in Table 3 . Tb illustrate the arithmetic, the data for ages 55 to 64 and dose 30 to 40 are reproduced from Table 2, as Table 16 .
In Table 3 , there is a cell corresponding to ages 55 to 64 and dose 30 to 40. The number of events in that cell is obtained by adding the numbers of events in the basic 50-54.) For the ACS volunteers, the data provided to us were already in the form of a cross-tab, with age and years since quit for ex-smokers at baseline in 1959. The study period was 1960 to 1965, so we added 4 years to get current age. For ex-smokers, age at start was not collected.
By convention, the number of person-years in each basic cell is treated as a constant in the modeling. From leading to inefficient procedures; however, they are valid, and they evidently provide efficient-enough tests.
Models for Animal Data Introduction
For experimental data on animals, doses are set high, so the hazard is high, too. The Poisson distribution must be replaced by the binomial and hazards converted to probabilities. The process will be illustrated on the megamouse data (27) . and the Peto et al. results on skin cancer and aging (10) will be considered last.
Mathematical Preliminaries
Let h be the hazard in a multistage model. With the independence of competing risks, the probability of an animal getting cancer during the period t to t + s, conditional on having survived till the beginning of the period, is ex J I t } --exp(-h(t)s) [9] For the current-exposure group in the mega-mouse study, exposure starts at To = 0, and the formulas for h become simpler. Consider a model with n precancerous stages, of which m are potentially sensitive. Suppose To = 0, and exposure is continuous. Let N be the number of target cells. Assume the rate of progression through stage i is ai + bi d, when the dose rate is d. The a's and b's must be nonnegative; stage i is potentially sensitive if bi is allowed to be positive; the number of such stages is denoted m. The hazard rate at time t is essentially as follows (71):
Multiplying tn'l in Equation 10 , there is a polynomial in dose of degree m, with nonpositive roots; and only its m + 1 coefficients can be estimated. In general, data on the current-exposure group cannot determine which of the stages are the sensitive ones, although their number m can be estimated, and only certain products in the basic parameters N, ai, bi can be estimated. Identifiable parameters can be obtained by rewriting Equation 10 as 181 [10] h(t) = (co + c1d+ * * +Cmdm) tn-l where d is dose and t is time. The c's are estimable; t should be nonnegative, and the polynomial should hav nonpositive roots-a constraint which is hard to imp To capture the constraints, it is possible to factor dose polynomial, rewriting the hazard rate (Eq. 11)
The lead constant G is identifiable; and so are the if arranged in decreasing order. These r's must be i negative. For Equation 12 to make sense, the backgrc rates (the a's in Eq. 10) must be positive.
With ceased exposure, it matters which states are sitive. To model the mega-mouse data, we wanted to sider having two early stages sensitive. The calculus out of hand amazingly fast, but a direct computatic still feasible when the first and second stages are s( tive. If exposure starts at time To = 0 and ends at t T1, the hazard at a later time t is
Here, A represents background; B, the sensitivity of second stage; C, of the first stage; and D, both (4, 6) Mega-Mouse Study
The mega-mouse experiment did not focus on timE tumor, so the results do not fit naturally into the fra work of the multistage model. To see the problem n sharply, take for example the 336 mice assigned to a c group of 150 ppm with planned sacrifice at 24 monthr these, 130 survived to 24 months and were sacrifice that time; among the sacrificed animals, 100 had blad tumors. The ratio 100/130 represents prevalence, no cidence. Indeed, it is not known when these tumors veloped.
To model this data set, we entertained two polar sumptions: a) The counts represent incidence, tha tumors which arose during the month of sacrificE tumors are rarely fatal, so the counts represent nearl, the tumors that arose at or before the sacrifice ti Either assumption gives about the same likelihood f tion for the current exposure group, as will now be cussed.
The statistical analysis is performed by treating number of survivors as constant. The counts in the various cells are taken to be independent binomials; the number of trials is the number at risk in the cell. If assumption a holds, the probability of a mouse getting liver cancer in month t is given by Equation 9 , with s = 1 (the period is viewed as 1 month). If assumption b holds, the probability that an animal sacrificed at time t has cancer is [14] [12] P (,r < t) = 1 -exp I -| h(u)du } (29) . Combining data from sacrifice and spontaneous deaths would require explicit modeling of latency, which has been estimated for bladder and liver cancer as being about 6 months (72). Such modeling requires introducing further assumptions, which seem as drastic in their own way as assumption a. For other views, see Kalbfleisch et al. (5) or Malani and van Ryzin (73) .
For the current-exposure group in the mega-mouse ex-
[131 periment, the data are reported in a basic twodimensional cross-tab for dose x sacrifice time (28) . With the ceased-exposure group there is a third dimension, namely, the time at which exposure ended. The cell counts the in the basic cross-tab are taken to be independent binomial variables; in each cell, the event probability is given by Equation 9 with s = 1, and the number of trials is the number of sacrificed animals.
To stabilize the X2, we wanted to avoid sparse cells; nor e-to-was a sum of binomials attractive. Therefore, some dose tmex sacrifice groups with low dose or early sacrifice were tiore eliminated from the fitting. Tb some extent this choice was lose data-driven, but it was treated as deterministic in the S. Of statistical analysis. The impact of this move seems to be ,d at small (6 The models had grotesque chi-squareds, and the residuals showed most of the problem to come from a dose of 60 ppm and sacrifice at 24 months. After looking more closely at the data source (28) we convinced ourselves that there was a misprint in that cell, which reports 7/415 events, and an incidence rate of 17.1%. The rate looks plausible, and we changed the numerator to 0.171 x 415 = 71, agreeing with (13) . Table 20 reports the results of fitting multistage models of the form of Equation 12 to the liver tumor data in the Table 19 . Results on liver cancer from the mega-mouse study: Number of response/number sacrificed (12, 13, 27 19 ). There were 27 events in these cells, with a predicted 41 . This looks bad, but the censored observations tend to be the smaller ones. The bootstrap assigns a p-value of 14% to a test based on the statistic "predicted-observed" for the censored cells (6) .
We then looked at the eight-stage model with first and second stages sensitive. This was marginal on the main group of cells, and looked fine on the censored ones (26 predicted, 27 observed, although the bias is still there). The model did not fit the ceased-exposure group (X2 = 41 on 24 degrees of freedom). Again, the residuals were too positive.
Brown and Hoel
Brown and Hoel (13) fit a multistage model to the liver data. We fully agree with their conclusion:
The way in which dose is represented in the model may be very consequential, and [this] illustrates the basic difficulties one may encounter when attempting to conclude with confidence anything about the initiation/promotion mechanisms based on tumor count data.
In general termns, our results are consistent with theirs, but there are some points of disagreement: we like seven stages with two sensitive, they like six stages with one sensitive, or four with two sensitive. They seem to be following assumption b and Equation 14, so seven of our stages correspond to six of theirs; however, we cannot fit a seven-stage model with one sensitive, or a five-stage model with two sensitive.
One reason for the discrepancies seems to be Brown and Hoel's decision to eliminate the group sacrificed at 33 months, based on examination of residual plots; the plots may show the heterogeneity we picked up in crossvalidation. Another reason is the choice of functional form: they include a constant latency parameter, make a nonstandard adjustment for background, and have a dose threshold effect.
We are using x2 = I (obs-exp)2/var, Brown = 0 and C > 0, the first stage is the only sensitive one and the only one with no background rate. If A = B = C = 0 and D > 0, then the first and next-to-last stages are sensitive but have no background rates; the other stages have positive background rates. If A = B = 0 but C > 0 and D > 0, then the first and next-to-last stages are sensitive; all stages but the first have positive background rates (6) . If the first and next-to-last stages are both sensitive, the dose response would be quadratic: Peto et al.
were concerned whether their results are compatible with quadratic dose response (10) . Partly on biological grounds by mainly on statistical ones, Peto et al. adopted a 28-week latency period between the transition to the cancerous state for a cell and the appearance of a tumor. As a result, they fit a hazard rate of the form (duration -28)3, that is, a four-stage model. We do not use the lag, and find a six-stage model gives the best fit, with a x2 = 67 on 37 degrees of freedom; the lagged model fits a little better with x2 = 60. Results might be cross-validated on data in Lee and O'Neill (74) .
The large values of X2 in Table 23 are mainly due to two or three cells, where the differences between observed and expected are substantial. This could have been an artifact of the aggregation. So we reaggregated, making some effort to eliminate the discrepancies. ( [86] [87] [88] .) The estimated coefficients stayed about the same, but the X2 only dropped imperceptibly, from 67 to 64. The incidence rates are sufficiently irregular that we stopped trying to fit models.
Peto et al. are trying to show that cancer results from the duration of exposure to the carcinogen, rather than the effect of time per se. The experiment and the associated arguments are interesting but hardly conclusive, even setting aside the question of whether the model fits the data.
In the multistage framework, the rate of progression through the stages depends on dose but not time and that seems to be a critical point in the argument. If, for example, the rate of progression through a stage really was time-dependent, Peto In this alternative model, a cell starts to age only after it has been moved out of stage one by the benzpyrene, which is not so far-fetched, given that Peto et al. are studying a tumor that does not occur spontaneously. The hazard rate in the second stage is time-dependent, so time per se plays a role in carcinogenesis. In short, no argument about the effect of time itself seems likely to succeed until the stages are better defined.
The alternative model may seem artificial, but no more so than the multistage model itself. The construction may also prompt the question, Why should the hazard rate be time-dependent? However, insisting on multistage models with hazard rates be depending only on dose is simply to decide the question of age versus duration on an a priori basis. The expected value is computed with respect to E. Asymptotically, the inverse of I(e) gives the variancecovariance matrix of the MLE, at E. Ordinarily, the MLE e will be substituted for E, to get a sample-based estimate The Fisher SEs are the square roots of the diagonal elements of I(e)-1. In particular, these can be computed from the data; the unknown parameter is not involved. Observed information may also be used.
Technical Details
Regularity conditions are given in Lehmann (36) , for example, and exclude cases where E falls on the boundary, corresponding to 0's for B or C in the present application. For some positive results on the boundary, see Freedman and Navidi (6) .
The matrix I(o) is nonnegative definite, but not necessarily positive definite. With the mega-mouse liver data, at the MLE 6, we found I(E1) to be rank-deficient, suggesting a singular distribution for 6.
Computational Details
Most of the computer work was done in FORTRAN on a VAX 750, with many of the calculations replicated somewhat independently in True BASIC on an IBM PC-XT. A few were replicated quite independently by Duncan Thomas at USC, but this does not imply that he agrees (or disagrees) with our conclusions.
Ti find the maximum of the log likelihood function, we used a computer routine written by NAG (Numerical Algorithm Group). This starts searching from a given initial point; it either reports failure to converge or finds the maxium. Usually, as best we can tell, it does find the global maximum; occasionally, it is fooled by a local maximum.
The algorithm was started from several points to see if there were multiple maxima and derivatives of the likelihood function were checked at each reported value to make sure this was at least a local maximum. In almost all the data sets described above, the algorithm found only one value, which we believe to be the global maximum. There was an exception: in fitting all 56 cells of the megamouse liver data, NAG's first pick was a saddle point on the line ri = r2.
